Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present) [0.03%]
CARM1抑制剂专利透视（2018-今）
Monica Viviano,Alessandra Cipriano,Alessandra Feoli et al.
Monica Viviano et al.
Introduction: CARM1 (Coactivator-associated arginine methyltransferase 1), also known as PRMT4 (Protein Arginine Methyltransferase 4), is a type I PRMT that regulates gene expression by methylating both histone and non-hi...
A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 - present) [0.03%]
2020年至今Mpro蛋白酶抑制剂治疗COVID-19的专利审查
Václav Mik,Laila S Benz,Jiří Voller et al.
Václav Mik et al.
Introduction: The SARS-CoV-2 main protease (Mpro, also known as 3CLpro or nsp5) is essential for viral replication. As there are no close human homologs, it represents an attractive and specific target for antiviral thera...
Patent landscape in hydroxamic acid-based HDAC inhibitors (2020-2024): structure-activity relationships and mechanistic insights [0.03%]
基于羟胺酸的HDAC抑制剂（2020-2024）专利图谱：结构-活性关系及机制见解
Ekta Shirbhate,Vaibhav Singh,Vidya Prabha et al.
Ekta Shirbhate et al.
Introduction: The hydroxamic acid-based histone deacetylase (HDAC) inhibitors play a crucial role as anticancer chemotherapeutics. It controls cellular pathways and epigenetically modify gene expression, making them impor...
Maria Fuertes,Endika Martín-Encinas,Asier Selas et al.
Maria Fuertes et al.
Introduction: Among the different topoisomerases, essential enzymes that play an important role in DNA processes such as replication and transcription, type I enzymes are targets of particular clinical importance for anti...
Emanuele Fabbrizi,Francesco Fiorentino,Antonello Mai et al.
Emanuele Fabbrizi et al.
Introduction: Sirtuins have gained significant prominence in scientific research due to their involvement in a wide array of biological processes, including DNA repair, genome stability, transcription modulation, and sign...
Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019-2024) [0.03%]
苯氧基硼化合物的治疗应用：专利和文献分析（2019-2024）
Simone Giovannuzzi,Alessio Nocentini,Claudiu T Supuran et al.
Simone Giovannuzzi et al.
Introduction: Benzoxaborole is a boron-based heterocyclic scaffold with remarkable potential in medicinal chemistry. Its unique chemical structure and compatibility with biological systems have enabled the development of ...
Medicinal chemistry perspective of ERK1/2 inhibitors in cancer treatment: an updated patent review (2019-present) [0.03%]
ERK1/2抑制剂抗癌专利盘点(2019-至今)——药物化学视角
Ankit Kumar Singh,Ajad Chauhan,Vineet Prajapati et al.
Ankit Kumar Singh et al.
Introduction: The mitogen-activated protein kinase (MAPK) pathway also known as the RAS/RAF/MEK/ERK pathway is a vital intracellular signaling cascade that regulates apoptosis, differentiation, proliferation, and signal t...
EOTP-2025-ST-0028.R1Insights and trends in development of TEAD-YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025) [0.03%]
TEAD-YAP/TAZ抑制剂开发的洞察与趋势：2022年6月至2025年PCT专利综述
Te Fan,Zhong Yu,Aiping Xiao et al.
Te Fan et al.
Introduction: The transcription enhancer associated domain (TEAD) family has been well documented for its roles in modulating cancer development, primarily through interactions with its two co-activators: yes-associated p...
An updated patent review of small molecule glucagon receptor antagonists (2020-2024) [0.03%]
2020-2024年小分子胰高血糖素受体拮抗剂专利分析
Chunyang Wang,Liyang Lyu,Dongyang Liu et al.
Chunyang Wang et al.
Introduction: The glucagon receptor (GCGR) plays a pivotal role in diabetes management. While small molecule GCGR antagonists (GCGRAs) offer several advantages, including glycemic control, oral bioavailability, and cost-e...
Bo-Wen Wan,Cheng-Shi Jiang,Chunlin Zhuang
Bo-Wen Wan
Introduction: Mixed-spectrum kinase structural domain-like protein (MLKL), which emerged as a pivotal regulator in biomedical research, plays a critical role in necroptotic pathways. Recent advancements have underscored t...